Ovarian cancer: strategies for overcoming resistance to chemotherapy

Nat Rev Cancer. 2003 Jul;3(7):502-16. doi: 10.1038/nrc1123.


Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Biomarkers
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm / physiology*
  • Female
  • Humans
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasms, Glandular and Epithelial / drug therapy*
  • Neoplasms, Glandular and Epithelial / therapy
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / therapy
  • Treatment Failure


  • Antineoplastic Agents
  • Biomarkers